Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Molnupiravir reduces severe illness and death, but it must be started within days after developing symptoms.
Collins has led the NIH under three presidents over more than 12 years.
A steady stream of spurious claims about COVID-19 vaccines and treatments swirl around the public consciousness.
Experts call for heightened precautions and better, more intensive therapies for COVID-19 patients with weakened immune systems.
The government-wide effort aims to develop the next generation of COVID-19 treatments to prepare the U.S. to respond to future virus threats
Molnupiravir, previously studied for hepatitis C, might be able to prevent or treat COVID-19 outside of a clinical setting.
The antiviral drug is the first treatment for the new coronavirus to be approved in United States.
The study asks whether certain approved therapies or late-stage investigational drugs show promise against COVID-19.
The HIV protease inhibitor combination did not speed recovery or reduce the risk of death in a large study.
Plasma from recovered patients recently received a controversial FDA emergency use authorization as a potential treatment for COVID-19.
However, experts caution that data from randomized clinical trials are still lacking.
Dexamethasone reduced mortality by up to a third among severely ill patients who needed supplemental oxygen or ventilators.
Tests like the one approved this week can show who is likely to be immune, but it’s not yet clear how long such immunity lasts.
The protease inhibitor combination did not work significantly better than supportive care, though those treated earlier might benefit.
Gilead Sciences is giving its antiviral remdesivir to nearly 1,000 people as part of two clinical trials.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.